Last reviewed 2026-04-23 · How we verify

Lanreotide microparticles

Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.

Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones. Used for Acromegaly, Neuroendocrine tumors (gastroenteropancreatic and thoracic), Carcinoid syndrome.

At a glance

Mechanism of action

Lanreotide acts as a long-acting somatostatin receptor agonist, mimicking the inhibitory effects of endogenous somatostatin. The microparticle formulation provides sustained release of the active peptide, allowing for extended suppression of growth hormone, insulin-like growth factor-1 (IGF-1), and other neuroendocrine hormones. This mechanism is used to control symptoms and slow tumor growth in neuroendocrine tumors and acromegaly.

Approved indications

• Acromegaly
• Neuroendocrine tumors (gastroenteropancreatic and thoracic)
• Carcinoid syndrome

Common side effects

• Diarrhea
• Abdominal pain
• Nausea
• Injection site reactions
• Steatorrhea
• Cholelithiasis

Key clinical trials

• Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis (PHASE3)
• Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lanreotide microparticles CI brief — competitive landscape report
• Lanreotide microparticles updates RSS · CI watch RSS
• Ipsen portfolio CI